Loading...
•
Sep 30, 2024
UroGen Q3 2024 Earnings Report
UroGen reported third quarter financial results and business highlights, including the potential launch of UGN-102 in 2025.
Key Takeaways
UroGen Pharma reported JELMYTO net product revenues of $25.2 million for Q3 2024, compared to $20.9 million for Q3 2023. The FDA accepted the New Drug Application for UGN-102, with a PDUFA target action date set for June 13, 2025. As of September 30, 2024, the company had $254.2 million in cash, cash equivalents, and marketable securities.
FDA accepted the New Drug Application for UGN-102 with a PDUFA target action date of June 13, 2025.
JELMYTO achieved net product sales of $25.2 million in Q3 2024, compared to $20.9 million in Q3 2023.
Cash, cash equivalents, and marketable securities totaled $254.2 million as of September 30, 2024.
First patient was dosed in the Phase 3 UTOPIA clinical trial of UGN-103 in October 2024.
Revenue by Segment
Forward Guidance
UroGen expects full-year JELMYTO revenues to be below the low end of the previous guidance range but anticipates low double-digit year-over-year revenue growth for the full year 2024. The company expects operating expenses to be toward the midpoint of the guidance range, including non-cash share-based compensation expense of $9 to $13 million. The anticipated full year 2024 non-cash financing expense related to the prepaid obligation to RTW Investments is expected to be in the range of $21 to $26 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...